Company Description
Daré Bioscience, Inc. develops therapies in the areas of contraception, pelvic pain, fertility, infectious disease, menopause, and sexual and vaginal health in the United States.
The company offers XACIATO, a lincosamide antibacterial gel for the treatment of bacterial vaginosis.
It also develops Ovaprene, a hormone-free monthly intravaginal contraceptive; Sildenafil Cream, a cream formulation of sildenafil for topical administration to the female genitalia for the treatment of female sexual arousal disorder; DARE-HRT1 to treat vasomotor symptoms in menopausal hormone therapy; DARE-VVA1 for the treatment of dyspareunia or pain during sexual intercourse; and DARE-HPV, a fixed-dose formulation of lopinavir and ritonavir in a soft gel vaginal insert to treat genital human papillomavirus (HPV) infection, cervical intraepithelial neoplasia, and other HPV-related pathologies.
In addition, the company develops DARE-PDM1, a hydrogel formulation of diclofenac for vaginal administration to treat primary dysmenorrhea; DARE-204 and DARE-214, injectable formulations of etonogestrel that provides contraception over 6-month and 12-month periods; DARE-FRT1, an intravaginal ring designed to deliver bio-identical progesterone for luteal phase support as part of an in vitro fertilization treatment plan; and DARE-PTB1 for the prevention of preterm birth.
Further, it develops DARE-LARC1, a contraceptive implant delivering levonorgestrel with a woman-centered design controlled contraceptive option; DARE-RH1, an approach to non-hormonal contraception for men and women by targeting the CatSper ion channel; DARE-PTB2 for the prevention and treatment of idiopathic preterm birth through inhibition of a stress response protein; DARE-LBT, a vaginal thermosetting gel formulation for the delivery of live biotherapeutics; and DARE-GML, which delivers antimicrobial glycerol monolaurate intravaginally.
Daré Bioscience, Inc. was founded in 2015 and is headquartered in San Diego, California.
| Country | United States |
| Founded | 2015 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 23 |
| CEO | Sabrina Johnson |
Contact Details
Address: 3655 Nobel Drive, Suite 260 San Diego, California 92122 United States | |
| Phone | 858 926 7655 |
| Website | darebioscience.com |
Stock Details
| Ticker Symbol | DARE |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001401914 |
| CUSIP Number | 23666P101 |
| ISIN Number | US23666P2002 |
| Employer ID | 20-4139823 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Sabrina Martucci Johnson | Chief Executive Officer, President, Principal Financial Officer, Secretary and Director |
| MarDee J. Haring-Layton | Chief Accounting Officer |
| Mark Walters | Vice President of Operations |
| Dr. David Friend Ph.D. | Chief Scientific Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jun 25, 2025 | 8-K | Current Report |
| Jun 12, 2025 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Jun 9, 2025 | 8-K | Current Report |
| May 13, 2025 | 10-Q | Quarterly Report |
| May 13, 2025 | 8-K | Current Report |
| Apr 24, 2025 | ARS | Filing |
| Apr 24, 2025 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 24, 2025 | DEF 14A | Other definitive proxy statements |
| Apr 11, 2025 | 8-K | Current Report |
| Mar 31, 2025 | 10-K | Annual Report |